Article Text

Download PDFPDF

AB0253 Tips on selection of biologics for patients with rheumatoid arthritis based on treatment patterns
  1. M Kamiya1,
  2. S Soen1,
  3. H Kikuchi2,
  4. N Okada3
  1. 1Department of Orthopaedic Surgery and Rheumatology, Kindai University Nara Hospital, Ikoma-City
  2. 2Department of Orthopaedic Surgery and Rheumatology, Kindai University Sakai Hospital, Sakai-City
  3. 3Department of Orthopaedic Surgery, Sumoto Itsuki Hospital, Sumoto-City, Japan


Background The emergence of biologics has led to innovation in the treatment of rheumatoid arthritis (RA). In the clinical setting, biologics are administered with careful consideration of complications and medical history in accordance with the treat-to-target recommendations. However, the progression of joint damage, the costs incurred before finding an effective biologic are serious concerns. It is therefore desirable to use biologics with long-term efficacy and less financial burden from the early stage.

Objectives Participants were RA patients treated with one of three biologics having different mechanisms of action who achieved therapy targets with long-term treatment efficacy and consequently achieved either reduction or withdrawal of therapy. Patients' background characteristics and long-term treatment patterns were evaluated.

Methods Between November 2004 and October 2016, 196, 57, and 85 RA patients were treated with etanercept (ETN), tocilizumab (TCZ), and abatacept (ABT), respectively, in first- or second-line therapy. These patients were divided into the continuation group, who underwent therapy with the same agent for ≥3 years without disease flare (DAS28-ESR >3.2) persisting 3 months, and the discontinuation group, who experienced primary failure resulting in discontinuation of the therapy within 3 months. Student's t test or Mann-Whitney's U test were used to compare patients' background characteristics between the two groups for each biologic. Further, log-rank test and Steel-Dwass test, respectively, were used to compare therapy continuation rates and reasons for discontinuation among the three biologics. Finally, relative dose intensity (RDI) was calculated to evaluate the treatment patterns of the individual biologics.

Results The Kaplan-Meier method showed that the 3-year continuation rates of therapy with ETN, TCZ, and ABT were 54.2%, 23.8%, and 35.8%, respectively: the continuation rate of ETN was significantly higher than that of the other two agents. The numbers of patients treated with ETN, TCZ, and ABT were respectively 46, 9, and 14 in the continuation group and 16, 12, and 11 in the discontinuation group. The proportion of patients treated with ETN plus concomitant MTX was significantly higher in the continuation group than in the discontinuation group (P=0.0057). No significant differences were found in patients' background characteristics (disease duration, rheumatoid or anti-cyclic citrullinated peptide positivity, number of biologics previously used, and DAS28-ESR). Mean RDI values (median value, 95% confidence interval) over a 3-year period were as follows: 0.95 (0.92, 0.83–1.06) for 25 mg/week ETN therapy; 0.78 (0.90, 0.66–0.89) for 50 mg/week ETN therapy; 0.84 (0.84, 0.76–0.89) for TCZ therapy; and 0.87 (0.94, 0.79–0.95) for ABT therapy. The cumulative costs for 3 years of the respective treatments were 19,700, 32,200, 27,300, and 39,000 euros (1 euro =115 Japanese yen). After targets were reached, the dose of ETN was maintained at 25 mg/week or reduced from 50 mg/week, while the TCZ and ABT therapies were continued over the long term with a longer dosing interval.

Conclusions Treatment with ETN plus concomitant MTX showed high continuation rates, and long-term achievement of therapy targets was maintained at a lower dosage (and thus, lower costs). It is beneficial to choose this method over non-TNF inhibitors.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.